1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–650. [PubMed] 2. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129. [PubMed] 3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–1259. [PMC free article] [PubMed]
4. Foundation NO. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
5. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(13):1917–1923. [PubMed] 6. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15(6):703–709. [PubMed] 7. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS. 2004;18(3):475–483. [PubMed] 8. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15(6):807–808. [PubMed] 9. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(4):F63–F67. [PMC free article] [PubMed] 10. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46(4):221–227. [PubMed] 11. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617–623. [PMC free article] [PubMed] 12. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42(7):1014–1020. [PubMed] 13. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19(7):913–918. [PubMed] 14. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16(11):1345–1352. [PMC free article] [PubMed] 15. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174. [PubMed] 16. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554–561. [PubMed] 17. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1–infected patients. HIV Clin Trials. 2007;8(3):164–172. [PubMed] 18. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with non-nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23(7):817–824. [PubMed] 19. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861–868. [PubMed] 20. Bolland MJ, Grey AB, Horne AM, et al. Bone mineral density is not reduced in HIV-infected caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2006;65(2):191–197. [PubMed] 21. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91(8):2938–2945. [PMC free article] [PubMed] 22. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus–infected individuals. Clin Infect Dis. 2003;36(4):482–490. [PubMed]
23. Dao C, Young B, Buchacz K, et al. Higher and increasing rates of fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared to the general US population, 1994 to 2008 [abstract 128]. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; 18 February 2010; San Francisco, CA.
24. Womack J, Goulet J, Gibert C, et al. HIV-infection and fragility fracture risk among male veterans [abstract 129]. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; 18 February 2010; San Francisco, CA.
25. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499–3504. [PubMed] 26. Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23(8):1021–1024. [PMC free article] [PubMed] 27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201. [PubMed]
28. Overton E, Mondy K, Bush T, et al. Factors associated with low bone mineral density (BMD) in a chort of HIV-Infected U.S. adults—baseline results from the SUN study [abstract 836]. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 26 February 2007; Los Angeles, CA.
29. Tebas P, Umbleja T, Dube M. Initiation of ART is associated with bone loos independent of the specific ART regimen: Results of ACTG A5005s [abstract 837]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 26 February 2007; Los Angeles, CA.
30. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150(1):67–78. [PubMed]
31. Borderi M, Gibellini D, Crignis ED, et al. HIV-1 Induces apoptosis in primary osteoblasts: an alternative mechanism in the development of osteopenia and osteoporosis [abstract 759]. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, Canada.
32. Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol. 2008;80(9):1507–1514. [PubMed] 33. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab. 1995;80(11):3351–3355. [PubMed]
34. Guaraldi G, Orlando G, Squillace N, et al. Prevalence of secondary causes of osteoporosis among HIV-infected individuals. Program and abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; San Francisco, CA. 24–26 September 2006.
35. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009;25(1):9–14. [PubMed] 36. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83(5):1135–1141. [PubMed] 37. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodeficiency virus–1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) Eur J Med Res. 2009;14(2):59–64. [PMC free article] [PubMed] 38. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009;122(5):409–414. [PubMed] 39. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab. 2009;94(9):3387–3393. [PubMed] 40. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89(3):1200–1206. [PubMed] 41. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86(8):3533–3539. [PubMed]
42. McComsey GA, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [abstract 106LB]. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; 16–19 February 2010; San Francisco, CA.
43. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39–48. [PubMed] 44. Fernandez-Rivera J, Garcia R, Lozano F, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003;4(5):337–346. [PubMed] 45. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19(3):402–409. [PubMed] 46. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17(4):513–520. [PubMed] 47. Dusso A, Vidal M, Powderly W, Yarashesky K, Tebas P. Protease inhibitors inhibit in vitro conversion of 25[OH]-vitamin D to 1,25[OH]2-vitamin D. Antivir Ther. 2000;5:19. [PubMed]
48. Cooper DA, Bloch M, Humphries A, et al. Simplification with fixed-dose tenofovir-emtricitaine or abacavir-lamivudine in adults with suppressed HIV repliation (The Steal Study): A randomized, open-label, 96-week, non-inferiority trial [abstract 576]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009; Montreal, Canada.
49. Stellbrink H, Moyle G, Orkin C, et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naive HIV-1 infected subjects. ASSERT: 48-Week Result. Program and abstracts of the 12th European AIDS Conference; 11–14 November 2009; Cologne, Germany.
50. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 2008;13(8):1077–1082. [PubMed] 51. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75(6):1392–1399. [PubMed] 52. Fabbriciani G, De Socio GV. Efavirenz and bone health. AIDS. 2009;23(9):1181. [PubMed] 53. Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS. 2009;23(2):274–275. [PubMed] 54. Landriscina M, Altamura SA, Roca L, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer. 2008;122(12):2842–2850. [PubMed] 55. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72(1):1–9. [PubMed] 56. Mora S, Gilsanz V. Establishment of peak bone mass. Endocrinol Metab Clin North Am. 2003;32(1):39–63. [PubMed] 57. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–1121. [PubMed] 58. Webber CE, Sala A, Barr RD. Accounting for body size deviations when reporting bone mineral density variables in children. Osteoporos Int. 2009;20(1):113–121. [PubMed] 59. Gertner JM, Kaufman FR, Donfield SM, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr. 1994;124(6):896–902. [PubMed] 60. Moye J, Jr, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group. J Pediatr. 1996;128(1):58–69. [PubMed] 61. Wren TA, Kim PS, Janicka A, Sanchez M, Gilsanz V. Timing of peak bone mass: discrepancies between CT and DXA. J Clin Endocrinol Metab. 2007;92(3):938–941. [PubMed] 62. Arpadi S, Horlick M, Shane E. Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89(1):21–23. [PubMed] 63. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr. 2002;29(5):450–454. [PubMed] 64. Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005;41(3):339–346. [PubMed] 65. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15(14):1823–1829. [PubMed] 66. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89(1):24–28. [PubMed] 67. Mora S, Zamproni I, Giacomet V, Cafarelli L, Figini C, Vigano A. Analysis of bone mineral content in horizontally HIV-infected children naive to antiretroviral treatment. Calcif Tissue Int. 2005;76(5):336–340. [PubMed] 68. O’Brien KO, Razavi M, Henderson RA, Caballero B, Ellis KJ. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001;73(4):821–826. [PubMed] 69. Pitukcheewanont P, Safani D, Church J, Gilsanz V. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements. Osteoporos Int. 2005;16(11):1393–1396. [PubMed] 70. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152(4):582–584. [PMC free article] [PubMed] 71. Rosso R, Vignolo M, Parodi A, et al. Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and anti-retroviral therapy. AIDS Res Hum Retroviruses. 2005;21(11):927–932. [PubMed] 72. Soler Palacin P, Torrent A, Rossich R, et al. Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child. J Pediatr Endocrinol Metab. 2007;20(8):933–938. [PubMed] 73. Tan BM, Nelson RP, Jr, James-Yarish M, Emmanuel PJ, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active antiretroviral therapy including a protease inhibitor. J Pediatr. 2001;139(3):447–451. [PubMed] 74. Vignolo M, Rosso R, Parodi A, Viscoli C. Quantitative ultrasound and bone density in vertically HIV-infected children. Clin Infect Dis. 2006;43(1):112–113. author reply, 3–4. [PubMed] 75. Stagi S, Bindi G, Galluzzi F, Galli L, Salti R, de Martino M. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. Clin Endocrinol Oxf. 2004;61(6):692–699. [PubMed] 76. Matarazzo P, Palomba E, Lala R, et al. Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr. 1994;83(10):1029–1034. [PubMed] 77. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):e846–e854. [PubMed] 78. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010;24(5):687–696. [PMC free article] [PubMed] 79. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006;64(5 Pt 1):226–233. [PubMed] 80. Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr. 2004;80(6 Suppl):1725S–1729S. [PubMed] 81. Puri S, Marwaha RK, Agarwal N, et al. Vitamin D status of apparently healthy schoolgirls from two different socioeconomic strata in Delhi: relation to nutrition and lifestyle. Br J Nutr. 2008;99(4):876–882. [PubMed] 82. Dannhauser A, van Staden AM, van der Ryst E, et al. Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa: anthropometric and dietary profile. Eur J Clin Nutr. 1999;53(3):165–173. [PubMed] 83. Sachan A, Gupta R, Das V, Agarwal A, Awasthi PK, Bhatia V. High prevalence of vitamin D deficiency among pregnant women and their newborns in northern India. Am J Clin Nutr. 2005;81(5):1060–1064. [PubMed] 84. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651–681. [PubMed] 85. Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res. 2004;19(5):764–772. [PubMed] 86. McComsey GA, Huang JS, Woolley IJ, et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care Chic Ill. 2004;3(3):86–91. [PubMed] 87. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87(10):4431–4437. [PubMed] 88. Cohen A, Fleischer J, Freeby MJ, McMahon DJ, Irani D, Shane E. Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health Larchmt. 2009;18(1):79–84. [PMC free article] [PubMed]
89. Cohen A, Shane E. In: Primer on the metabolic bone diseases and other disorders of bone and mineral metbolism: premenopausal osteoporosis. 7. Rosen C, editor. New York: JW Wiley; 2008.
90. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441–464. [PubMed] 91. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92(12):4522–4528. [PubMed] 92. Chew NS, Doran PP, Powderly WG. Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Curr Opin HIV AIDS. 2007;2(4):318–323. [PubMed] 93. Pollock E, Klotsas AE, Compston J, Gkrania-Klotsas E. Bone health in HIV infection. Br Med Bull. 2009;92:123–133. [PubMed] 94. Kanis J, Johnell O, Gullberg B, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int. 1999;9(1):45–54. [PubMed] 95. Melton LJ, 3rd, Atkinson EJ, Khosla S, O’Fallon WM, Riggs BL. Secondary osteoporosis and the risk of vertebral deformities in women. Bone. 1999;24(1):49–55. [PubMed] 96. Poor G, Atkinson EJ, O’Fallon WM, Melton LJ., 3rd Predictors of hip fractures in elderly men. J Bone Miner Res. 1995;10(12):1900–1907. [PubMed] 98. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72–81. [PubMed] 99. Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1998;129(2):81–88. [PubMed] 100. Rosen H, Drezner M. In: Overview of the management of osteoporosis in women. Rose B, editor. Wellsley, MA: UpToDate Online 18.2, 2010. http://www.uptodateonline.com. 101. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387–5391. [PubMed] 102. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93(8):3015–3020. [PubMed] 103. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9(1):107–118. [PubMed] 104. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. [PubMed] 105. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–1822. [PubMed] 106. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr. 2006;136(4):1117–1122. [PubMed] 107. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12(1):48–53. [PubMed] 108. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20(2):239–244. [PubMed] 109. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–S21. [PubMed] 110. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473–2482. [PubMed] 111. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426–431. [PubMed] 112. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92(4):1283–1288. [PubMed] 113. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23(1):51–57. [PMC free article] [PubMed] 114. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial. 2007;20(3):186–190. [PubMed] 115. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36(3):478–490. [PubMed] 116. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1491. [PubMed] 117. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. [PubMed] 118. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89–90. [PubMed] 119. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–1301. [PubMed] 120. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20(8):1353–1362. [PubMed] 121. Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199. [PubMed] 122. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–1771. [PubMed] 123. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90(3):1897–1899. [PubMed] 124. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–1226. [PubMed] 125. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int. 1998;63(5):363–368. [PubMed]
126. Dolin R, Masur H, Saag M. In: Bone disorders. 3. Livingstone C, editor. Philadelphia, PA: Elsevier; 2008.